vain1
Showing 1 - 5 of 5
HPV Infections, Cervical Cancer, Vulvar Cancer Trial in Guangxi (Experimental: Experimental: 9-valent Human Papillomavirus
Completed
- HPV Infections
- +14 more
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
- Active Comparator: GARDASIL ®9
-
Guangxi, ChinaGuangxi Zhuang Autonomous Region Center for Disease Control and
May 9, 2022
HPV Infections, Cervical Cancer, Vulvar Cancer Trial in Hangzhou (9-valent HPV vaccine)
Recruiting
- HPV Infections
- +14 more
- 9-valent HPV vaccine
-
Hangzhou, ChinaHuakun Lv
Feb 23, 2022
Cervical Cancer, Vulvar Cancer, Vaginal Cancer Trial in Yangchun (4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL®)
Completed
- Cervical Cancer
- +13 more
- 4-valent HPV Vaccine
- +2 more
-
Yangchun, Guangdong, ChinaYangchun Center For Disease Prevention And Control
Feb 23, 2022
Cervical Cancer, Vulvar Cancer, Vaginal Cancer Trial in Rongan County (9-valent Human Papillomavirus (Types 6, 11, 16,
Recruiting
- Cervical Cancer
- +13 more
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
- GARDASIL®
-
Rongan County, Guangxi Zhuang Autonomous Region, ChinaRongan County Center for Disease Control and Prevention
Feb 20, 2022
Cervical Cancers, Vulvar Cancer, Vaginal Cancer Trial in Hanzhou (9-valent HPV Recombinant Vaccine, Placebo)
Completed
- Cervical Cancers
- +14 more
- 9-valent HPV Recombinant Vaccine
- Placebo
-
Hanzhou, ChinaZhejiang Provincial Center for Disease Control and Prevention
Jan 20, 2020